^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZN-A-1041

    i
    Other names: ZN-A-1041, RG6596, ZN-1041
    Company:
    Roche, Suzhou Zanrong
    Drug class:
    HER2 inhibitor
    Related drugs:
    9ms
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, Suzhou Zanrong Pharma Limited | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • ZN-A-1041
    over3years
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, Suzhou Zanrong Pharma Limited | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    capecitabine • ZN-A-1041
    almost4years
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Suzhou Zanrong Pharma Limited
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    capecitabine • ZN-A-1041